Since FFPE is the clinical standard for cancer diagnosis, examining samples in this manner will allow for high-throughput and sensitive quantitation of IR-A:IR-B ratios over what is typically a long course of clinical care and also help identify the subset of patients with altered IR-A:IR-B ratios that might respond to IGF-targeted therapy. This evidence concerns the gene IGF1 and cancer.